NEW YORK, January 20, 2017 /PRNewswire/ --
Stock-Callers.com today evaluates the following Drug Manufacturers equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). These stocks belong to the Healthcare sector which fell on Thursday, January 19th, 2017, finishing near its session lows. As per a NASDAQ report, the NYSE Health Care Index dropped over 0.7%, while shares of health care companies in the S&P 500 also were down 0.6% as a group. Learn more about these stocks by downloading their comprehensive and free reports at: http://stock-callers.com/registration
New York headquartered Synergy Pharmaceuticals Inc.'s shares declined 1.84%, closing Thursday's trading session at $6.41. The stock recorded a trading volume of 4.11 million shares. Shares of the Company have advanced 23.98% in the last month, 21.17% over the previous three months, and 5.25% on an YTD basis. The stock is trading 14.86% above its 50-day moving average and 40.42% above its 200-day moving average. Additionally, shares of Synergy Pharma, which focuses on the development of drugs to treat gastrointestinal disorders and diseases, have a Relative Strength Index (RSI) of 57.72.
On January 05th, 2017, research firm Oppenheimer initiated an 'Outperform' rating on the Company's stock.
On January 19th, 2017, Synergy Pharmaceuticals announced that the US FDA has approved TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation. TRULANCE is the first drug designed to replicate the function of uroguanylin, a naturally occurring and endogenous human gastrointestinal peptide that is thought to stimulate fluid secretion which results in a stool consistency associated with more regular bowel function. SGYP complete research report is just a click away and free at:
On Thursday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 1.44 million shares. The stock dropped 1.14%, ending the day at $35.63. The Company's shares have advanced 0.03% in the last month. The stock is trading above its 50-day moving average by 2.75%. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 51.55.
On December 05th, 2016, Novo Nordisk announced the submission of a New Drug Application (NDA) to the US FDA for semaglutide, a glucagon-like peptide-1 (GLP-1) analog administered once-weekly, for the treatment of adults with type-2 diabetes. The Company also submitted a Marketing Authorization Application to the European Medicines Agency for semaglutide. The complimentary report on NVO can be downloaded at:
Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc.'s stock finished the day 2.80% lower at $11.45 with a total trading volume of 749,292 shares. The Company's shares are trading below their 200-day moving average by 7.31%. Shares of the Company, which focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the US, Japan, Switzerland, and internationally, have an RSI of 28.19.
On December 22nd, 2016, research firm Mizuho upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $16 per share.
As per a SEC filing dated December 27th, 2016, Sucampo Pharmaceuticals on December 27th, 2016, issued $300.0 million aggregate principal amount of its 3.25% Convertible Senior Notes due 2021 (to Leerink Partners LLC (Initial Purchaser), who subsequently resold the Notes to qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A under the Securities Act of 1933, as amended. The Company estimates that the net proceeds from the Note Offering will be $290.4 million, after deducting the Initial Purchaser's discount and estimated offering expenses. Concurrently with the closing of the Note Offering, the Company intends to use the net proceeds from the Note Offering to repay in full approximately $238.4 million due under the Company's senior secured credit facility, including all accrued but unpaid interest and a prepayment premium. Sign up for your complimentary research report on SCMP at:
Shares in Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc. ended yesterday's session 7.87% lower at $2.81. The stock recorded a trading volume of 441,930 shares. The Company's shares have advanced 44.85% since the start of this year. The stock is trading 92.78% above its 200-day moving average. Moreover, shares of Pernix Therapeutics, which develops, manufactures, markets, and sells pharmaceutical products, have an RSI of 49.31.
On January 06th, 2017, Pernix Therapeutics announced the appointment of Ken Piña as Senior Vice President, General Counsel, and Chief Compliance Officer. Mr. Piña will report directly to John Sedor, Chairman and CEO, and will serve as the Company's senior in-house counsel, overseeing the legal and compliance area, and establishing legal and compliance strategies. Get free access to your research report on PTX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA